Brokers Set Expectations for Editas Medicine Q3 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Stock analysts at HC Wainwright raised their Q3 2026 earnings estimates for shares of Editas Medicine in a report issued on Thursday, August 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.20) per share for the quarter, up from their previous forecast of ($0.33). The consensus estimate for Editas Medicine’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Editas Medicine’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.66) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.21) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.70) EPS.

Several other analysts also recently commented on EDIT. TD Cowen restated a “buy” rating on shares of Editas Medicine in a research note on Wednesday, May 27th. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday. Chardan Capital increased their price target on Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Editas Medicine in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.40.

Editas Medicine Trading Down 2.4%

EDIT opened at $2.81 on Monday. The company has a fifty day moving average price of $2.89 and a two-hundred day moving average price of $2.65. Editas Medicine has a 1-year low of $1.66 and a 1-year high of $4.54. The company has a market cap of $275.13 million, a P/E ratio of -3.75 and a beta of 2.14.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.12. The business had revenue of $11.89 million for the quarter, compared to analyst estimates of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EDIT. BlackRock Inc. purchased a new stake in Editas Medicine during the second quarter valued at about $34,312,000. Renaissance Technologies LLC lifted its stake in shares of Editas Medicine by 30.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company’s stock valued at $9,811,000 after buying an additional 932,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Editas Medicine by 122.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after buying an additional 1,430,000 shares in the last quarter. Geode Capital Management LLC grew its stake in Editas Medicine by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company’s stock valued at $4,685,000 after buying an additional 244,574 shares in the last quarter. Finally, State Street Corp grew its stake in Editas Medicine by 2.6% in the 4th quarter. State Street Corp now owns 1,974,931 shares of the company’s stock valued at $4,049,000 after buying an additional 49,887 shares in the last quarter. Institutional investors own 71.90% of the company’s stock.

Insider Buying and Selling at Editas Medicine

In other news, CEO Gilmore Neil O’neill sold 15,380 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total transaction of $41,526.00. Following the completion of the sale, the chief executive officer owned 248,313 shares in the company, valued at $670,445.10. This trade represents a 5.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 21,503 shares of company stock worth $57,910. 3.10% of the stock is owned by corporate insiders.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.